Top-News

Aldeyra Therapeutics Aktie News

Aktie
WKN:  A111X8 ISIN:  US01438T1060 US-Symbol:  ALDX Branche:  Biotechnologie Land:  USA
4,84 $
-0,04 $
-0,82%
4,1542 € 16:32:02 Uhr
Depot/Watchlist
Marktkapitalisierung *
261,68 Mio. €
Streubesitz
38,84%
KGV
-5,31
Index-Zuordnung
-

Aldeyra Therapeutics News

12.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
06.05.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
28.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
24.04.25 - PR Newswire
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PR Newswire
22.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
22.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
14.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX PR Newswire
10.04.25 - PR Newswire
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman PR Newswire
16.02.25 - Boersia.de
Aldeyra Therapeutics Aktie: Starke Performance erfreut!
Die Aldeyra Therapeutics Aktie zeigt sich zum Stichtag 15. Februar 2025 in einer bemerkenswerten Aufwärtsbewegung. Mit einem aktuellen Kurs von 6,18 EUR verzeichnet das ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »